Voyager Therapeutics
Cambridge-based Voyager Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe CNS diseases.
Founded
2014Cambridge-based Voyager Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe CNS diseases.
Founded in Cambridge, Massachusetts, Voyager Therapeutics, Inc. is a clinical-stage gene therapy company dedicated to developing life-changing treatments for severe central nervous system (CNS) diseases. The company's core mission is to leverage the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Voyager Therapeutics focuses on creating transformative gene therapies aimed at treating fatal and debilitating CNS conditions.
Voyager Therapeutics has garnered attention through its affiliations with notable scientists and investors in the biotechnology sector. The company is publicly traded on Nasdaq under the ticker symbol VYGR. Key achievements include dosing participants in clinical trials and presenting at multiple investor conferences, showcasing their progress and potential impact. Voyager Therapeutics' innovative approach has positioned it as a significant player in the quest to develop effective treatments for severe neurological diseases.
Companies similar to Voyager Therapeutics include Poseida Therapeutics, Lacerta Therapeutics, Taysha Gene Therapies and Kriya Therapeutics.
Voyager Therapeutics was founded in 2014.
Voyager Therapeutics' headquarters is located in Cambridge, MA, US.
Voyager Therapeutics' most recent funding round was for $100M (USD) in January 2024.
As of Jan 4, 2024, Voyager Therapeutics has disclosed funding of $374M (USD). Undisclosed round amounts are excluded.
Voyager Therapeutics has 125 employees as of Feb 6, 2024.
Kriya Therapeutics
